logo

For the Inventor, By the Inventor

Richard Dennis DiMarchi

Carmel, IN, United States of America

Richard Dennis DiMarchi

LinkedIn

This inventor holds 111 USPTO granted patents and 34 published patent applications and 1 EPO patent, primarily in Incretin Biology (CPC class C07K14-605). Top assignees: Indiana University, Eli Lilly and Company, Ambrx, Inc.. Active years: 1986-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Dennis DiMarchi. Retrieved from https://idiyas.com/inventor/richard-dennis-dimarchi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 111 

% Patents Active = 51.4


Average Co-Inventor Count = 3.1

ph-index = 26

Forward Citations = 2,494(Granted Patents)

Forward Citations (Not Self Cited) = 2,252(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • Bloomington, IN (US) (2014)
  • Indianapolis, IN (US) (2017)
  • Carmel, IN (US) (1986 - 2023)

Company Filing History:

goldMedal52 out of 809 
 
Indiana University
 patents
silverMedal42 out of 4,514 
 
Eli Lilly and Company
 patents
bronzeMedal11 out of 117 
 
Ambrx, Inc.
 patents
4. 3 out of 1,802 
 
Novo Nordisk A/s
 patents
5. 2 out of 2 
 
Marcadia Biotech, Inc.
 patents
6. 2 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
7. 1 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents
8. 1 out of 1 
 
Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.r.l.
 patent
9. 1 out of 6 
 
Legacy Emanuel Hospital & Health Center
 patents
10. 1 out of 7 
 
Msd Italia S.r.l.
 patents
11. 1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1986-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
GLP-1 Receptor
GIP Receptor
Insulin Conjugates
Glucagon Peptides
Metabolic Disorders
Oral Delivery
Peptide Compounds
Stability
Diabetes Treatment
Hormone Activity
Agonist Conjugates
111 patents (USPTO):Explore Patents
1. 11779648 - Co-agonists at GLP-1 and GIP receptors suitable for oral delivery (2023-10-10),
2. 11633459 - GIP derivatives and uses thereof (2023-04-25),
3. 11351268 - FGF21 C-terminal peptide optimization (2022-06-07),
4. 10730923 - Glucagon/GLP-1 receptor co-agonists (2020-08-04),
5. 10696726 - Insulin-incretin conjugates (2020-06-30),
6. 10683334 - Aqueously soluble and chemically stable glucagon peptides (2020-06-16),
7. 10604555 - GIP derivatives and uses thereof (2020-03-31),
8. 10385107 - Lipidated amide-based insulin prodrugs (2019-08-20),
9. 10233225 - Single chain insulin agonists exhibiting high activity at the insulin receptor (2019-03-19),
10. 10232020 - Incretin-insulin conjugates (2019-03-19),
11. 10174093 - Glucagon/GLP-1 receptor co-agonists (2019-01-08),
12. 10137170 - Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides (2018-11-27),
13. 9868772 - Analogs of glucagon exhibiting GIP receptor activity (2018-01-16),
14. 9790263 - GIP receptor-active glucagon compounds (2017-10-17),
15. 9783592 - Glucagon superfamily peptides exhibiting nuclear hormone receptor activity (2017-10-10),

Title: The Innovative Journey of Richard Dennis DiMarchi

Introduction: Richard Dennis DiMarchi, a distinguished inventor hailing from Carmel, IN (US), has made significant contributions to the field of innovations and patents, particularly in the realm of biotechnology and pharmaceuticals.

Latest Patents: Richard Dennis DiMarchi holds several groundbreaking patents in the field of biopharmaceuticals, including novel drug delivery systems and therapeutic compounds designed to revolutionize the treatment of various medical conditions.

Career Highlights: With a stellar career spanning decades, Richard Dennis DiMarchi has held key positions in renowned research institutions and pharmaceutical companies, where he has spearheaded pioneering research projects leading to the development of life-changing medications.

Collaborations: Throughout his career, Richard Dennis DiMarchi has collaborated with top scientists, researchers, and industry experts to bring cutting-edge innovations to the forefront of the biotechnology and pharmaceutical sectors. His collaborative efforts have resulted in the successful development and commercialization of several patented inventions.

Conclusion: Richard Dennis DiMarchi's unwavering dedication to innovation and his relentless pursuit of scientific excellence have solidified his reputation as a trailblazer in the field of biopharmaceuticals. His remarkable contributions continue to shape the landscape of modern medicine, offering hope and healing to countless individuals worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…